A medical technology company focused on developing innovative technologies for early diagnosis of cancer, today announced new research results. A clinical study of liver cancer has demonstrated the great potential of LAM’s new DNA methylation-based biomarker to detect hepatocellular carcinoma (HCC) The detection sensitivity is 95% and the specificity is 97.5%.
In this study, stock samples of 130 subjects were collected, including: 60 subjects diagnosed with hepatocellular carcinoma (stage I to IV), 30 subjects without liver disease, 10 Subjects diagnosed with benign liver disease and 30 subjects diagnosed with breast cancer, colorectal cancer or lung cancer. DNA was extracted from the sample, the DNA was transformed with bisulfite, and DNA methylation was quantified using the IvyGene platform. After completing the data collection and analysis of all samples, blind the samples to calculate the test performance.
A total of 57 of the 60 samples taken from patients with hepatocellular carcinoma were correctly identified, with an overall calculated sensitivity of 95%. The sensitivity difference between detecting stage I and stage IV hepatocellular carcinoma was small (range 89% to 100%). Of the samples taken from cancer patients other than liver cancer, 90% of breast cancer samples, 80% of colorectal cancer samples, and 90% of lung cancer samples were correctly identified as non-liver cancer, and the total calculated specificity was 87%.
